Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M; Gruppo Italiano Cooperativo di Neuro-Oncologia. Brandes AA, et al. Among authors: ermani m. J Clin Oncol. 2004 May 1;22(9):1598-604. doi: 10.1200/JCO.2004.11.019. J Clin Oncol. 2004. PMID: 15117981 Clinical Trial.
Temozolomide in glioblastoma multiforme of the elderly.
Brandes AA, Vastola F, Basso U, Pasetto LM, Ermani M, Berti F, Rotilio A, Amistà P, Scienza R, Monfardini S. Brandes AA, et al. Among authors: ermani m. Tumori. 2002 Jan-Feb;88(1 Suppl 1):S69-70. doi: 10.1177/030089160208800120. Tumori. 2002. PMID: 11989929 Clinical Trial. No abstract available.
A prospective study on glioblastoma in the elderly.
Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, Gardiman M, Scienza R, Monfardini S, Ermani M. Brandes AA, et al. Among authors: ermani m. Cancer. 2003 Feb 1;97(3):657-62. doi: 10.1002/cncr.11097. Cancer. 2003. PMID: 12548608 Free article. Clinical Trial.
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M. Brandes AA, et al. Among authors: ermani m. J Clin Oncol. 2004 Dec 1;22(23):4779-86. doi: 10.1200/JCO.2004.06.181. J Clin Oncol. 2004. PMID: 15570079 Clinical Trial.
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M; GICNO. Brandes AA, et al. Among authors: ermani m. J Clin Oncol. 2006 Oct 10;24(29):4746-53. doi: 10.1200/JCO.2006.06.3891. Epub 2006 Sep 5. J Clin Oncol. 2006. PMID: 16954518 Clinical Trial.
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. Brandes AA, et al. Among authors: ermani m. J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163. J Clin Oncol. 2008. PMID: 18445844
227 results